Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial.

Falardeau J, Fryman A, Wanchu R, Marracci GH, Mass M, Wooliscroft L, Bourdette DN, Murchison CF, Hills WL, Yadav V.

Mult Scler J Exp Transl Clin. 2019 May 13;5(2):2055217319850193. doi: 10.1177/2055217319850193. eCollection 2019 Apr-Jun.

2.

Effect of High-Intensity Exercise on Multiple Sclerosis Function and Phosphorous Magnetic Resonance Spectroscopy Outcomes.

Orban A, Garg B, Sammi MK, Bourdette DN, Rooney WD, Kuehl K, Spain RI.

Med Sci Sports Exerc. 2019 Jul;51(7):1380-1386. doi: 10.1249/MSS.0000000000001914.

PMID:
31205251
3.

Effects of lipoic acid on primary murine microglial cells.

Chaudhary P, Marracci G, Pocius E, Galipeau D, Morris B, Bourdette D.

J Neuroimmunol. 2019 May 27;334:576972. doi: 10.1016/j.jneuroim.2019.576972. [Epub ahead of print]

PMID:
31176014
4.

Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis.

Waslo C, Bourdette D, Gray N, Wright K, Spain R.

Curr Treat Options Neurol. 2019 May 6;21(6):26. doi: 10.1007/s11940-019-0566-1. Review.

PMID:
31056714
5.

Myelin repair stimulated by CNS-selective thyroid hormone action.

Hartley MD, Banerji T, Tagge IJ, Kirkemo LL, Chaudhary P, Calkins E, Galipeau D, Shokat MD, DeBell MJ, Van Leuven S, Miller H, Marracci G, Pocius E, Banerji T, Ferrara SJ, Meinig JM, Emery B, Bourdette D, Scanlan TS.

JCI Insight. 2019 Apr 18;4(8). pii: 126329. doi: 10.1172/jci.insight.126329. eCollection 2019 Apr 18.

6.

Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?

Hartung DM, Johnston K, Deodhar A, Bourdette DN, Cohen DM.

Am J Kidney Dis. 2019 Feb 11. pii: S0272-6386(19)30005-8. doi: 10.1053/j.ajkd.2018.12.025. [Epub ahead of print]

PMID:
30765104
7.

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D.

Hartung DM, Johnston KA, Irwin A, Markwardt S, Bourdette DN.

Health Aff (Millwood). 2019 Feb;38(2):303-312. doi: 10.1377/hlthaff.2018.05357.

PMID:
30715973
8.

Effect of High-Intensity Exercise on Multiple Sclerosis Function and 31P MRS Outcomes.

Orban A, Garg B, Sammi MK, Bourdette DN, Rooney WD, Kuehl K, Spain RI.

Med Sci Sports Exerc. 2019 Jan 30. doi: 10.1249/MSS.0000000000001914. [Epub ahead of print]

PMID:
30707115
9.

Structure-Activity Relationships of Central Nervous System Penetration by Fatty Acid Amide Hydrolase (FAAH)-Targeted Thyromimetic Prodrugs.

Meinig JM, Ferrara SJ, Banerji T, Banerji T, Sanford-Crane HS, Bourdette D, Scanlan TS.

ACS Med Chem Lett. 2018 Dec 4;10(1):111-116. doi: 10.1021/acsmedchemlett.8b00501. eCollection 2019 Jan 10.

PMID:
30655956
10.

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.

Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN.

JAMA Netw Open. 2018 Jun 1;1(2):e180482. doi: 10.1001/jamanetworkopen.2018.0482.

11.

Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.

Loy BD, Fling BW, Horak FB, Bourdette DN, Spain RI.

Complement Ther Med. 2018 Dec;41:169-174. doi: 10.1016/j.ctim.2018.09.006. Epub 2018 Sep 22.

PMID:
30477834
12.

The key role of T cells in Parkinson's disease pathogenesis and therapy.

Baird JK, Bourdette D, Meshul CK, Quinn JF.

Parkinsonism Relat Disord. 2019 Mar;60:25-31. doi: 10.1016/j.parkreldis.2018.10.029. Epub 2018 Oct 28. Review.

PMID:
30404763
13.

Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.

Senders A, Hanes D, Bourdette D, Carson K, Marshall LM, Shinto L.

Mult Scler. 2019 Jul;25(8):1178-1188. doi: 10.1177/1352458518786650. Epub 2018 Jul 9.

PMID:
29985095
14.

Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.

Silbermann E, Wooliscroft L, Bourdette D.

Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):49. doi: 10.1007/s11910-018-0858-y. Review.

PMID:
29923130
15.

Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.

Ferrara SJ, Bourdette D, Scanlan TS.

Endocrinology. 2018 Jul 1;159(7):2733-2740. doi: 10.1210/en.2018-00065.

16.

A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.

Hugos CL, Cameron MH, Chen Z, Chen Y, Bourdette D.

Mult Scler. 2019 May;25(6):871-875. doi: 10.1177/1352458518775920. Epub 2018 May 15.

PMID:
29761722
17.

Uses of H.P. Acthar Gel in the Clinical Setting-Reply.

Hartung DM, Bourdette DN, Cohen DM.

JAMA Intern Med. 2018 Apr 1;178(4):583-584. doi: 10.1001/jamainternmed.2017.8545. No abstract available.

PMID:
29610884
18.

Meals, Mindfulness, & Moving Forward: A feasibility study to a multi-modal lifestyle approach in early psychosis.

Usher C, Thompson A, Griebeler M, Senders A, Seibel C, Ly R, Murchison C, Hagen K, Afong KA, Bourdette D, Ross R, Borgatti A, Shinto L.

Early Interv Psychiatry. 2019 Feb;13(1):147-150. doi: 10.1111/eip.12546. Epub 2018 Mar 7.

PMID:
29512356
19.

Elephant in the room.

Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar AA, Bourdette DN.

Ann Rheum Dis. 2019 Feb;78(2):e11. doi: 10.1136/annrheumdis-2018-213008. Epub 2018 Jan 23. No abstract available.

PMID:
29363509
20.

Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.

George JD, Kim E, Spain R, Bourdette D, Salinthone S.

J Neuroimmunol. 2018 Feb 15;315:24-27. doi: 10.1016/j.jneuroim.2017.12.009. Epub 2017 Dec 19.

PMID:
29306401
21.

A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.

Hugos CL, Chen Z, Chen Y, Turner AP, Haselkorn J, Chiara T, McCoy S, Bever CT Jr, Cameron MH, Bourdette D; VA MS Fatigue Study Group.

Mult Scler. 2019 Feb;25(2):275-285. doi: 10.1177/1352458517745723. Epub 2017 Dec 11.

PMID:
29226778
22.

Diet in multiple sclerosis: Science takes a seat at the table.

Sumowski JF, McDonnell GV, Bourdette D.

Neurology. 2018 Jan 2;90(1):14-15. doi: 10.1212/WNL.0000000000004775. Epub 2017 Dec 6. No abstract available.

PMID:
29212826
23.

Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Fiedler SE, Yadav V, Kerns AR, Tsang C, Markwardt S, Kim E, Spain R, Bourdette D, Salinthone S.

Mol Neurobiol. 2018 Jul;55(7):6037-6049. doi: 10.1007/s12035-017-0813-y. Epub 2017 Nov 15.

PMID:
29143287
24.

Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.

Winges KM, Murchison CF, Bourdette DN, Spain RI.

Mult Scler. 2019 Jan;25(1):55-62. doi: 10.1177/1352458517739136. Epub 2017 Nov 7.

PMID:
29111873
25.

Analysis of IL-6, IL-1β and TNF-α production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs.

Fiedler SE, George JD, Love HN, Kim E, Spain R, Bourdette D, Salinthone S.

J Syst Integr Neurosci. 2017 May;3(3). doi: 10.15761/JSIN.1000166. Epub 2017 Jun 17.

26.

MIF and D-DT are potential disease severity modifiers in male MS subjects.

Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, Du X, Sreih A, Leng L, Wiedrick J, Caillier SJ, Offner H, Oksenberg JR, Yadav V, Bourdette D, Bucala R, Vandenbark AA.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.

27.

Trends and Characteristics of US Medicare Spending on Repository Corticotropin.

Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN.

JAMA Intern Med. 2017 Nov 1;177(11):1680-1682. doi: 10.1001/jamainternmed.2017.3631. No abstract available.

28.

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Wiendl H, Bourdette D, Ciccarelli O.

Neurology. 2017 Sep 12;89(11):1098-1100. doi: 10.1212/WNL.0000000000004381. Epub 2017 Aug 23. No abstract available.

PMID:
28835406
29.

Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis.

Spain RI, Liu L, Zhang X, Jia Y, Tan O, Bourdette D, Huang D.

Br J Ophthalmol. 2018 Apr;102(4):520-524. doi: 10.1136/bjophthalmol-2017-310477. Epub 2017 Aug 16.

30.

Author response: Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette DN.

Neurology. 2017 Aug 1;89(5):520-521. doi: 10.1212/WNL.0000000000004194. No abstract available.

PMID:
28760917
31.

Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy.

Meinig JM, Ferrara SJ, Banerji T, Banerji T, Sanford-Crane HS, Bourdette D, Scanlan TS.

ACS Chem Neurosci. 2017 Nov 15;8(11):2468-2476. doi: 10.1021/acschemneuro.7b00239. Epub 2017 Aug 18.

32.

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS.

Bittner F, Murchison C, Koop D, Bourdette D, Spain R.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e380. doi: 10.1212/NXI.0000000000000380. eCollection 2017 Sep. No abstract available.

33.

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, Cameron M, Kim E, Horak F, Simon J, Bourdette D.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374. doi: 10.1212/NXI.0000000000000374. eCollection 2017 Sep.

34.

A group-delivered self-management program reduces spasticity in people with multiple sclerosis: A randomized, controlled pilot trial.

Hugos CL, Bourdette D, Chen Y, Chen Z, Cameron M.

Mult Scler J Exp Transl Clin. 2017 Mar 23;3(1):2055217317699993. doi: 10.1177/2055217317699993. eCollection 2017 Jan-Mar.

35.

MS and bone marrow transplant: Not for most patients.

Frederick MC, Bourdette D.

Neurology. 2017 May 30;88(22):e219-e220. doi: 10.1212/WNL.0000000000004001. No abstract available.

PMID:
28554907
36.

Sex-dependent treatment of chronic EAE with partial MHC class II constructs.

Benedek G, Chaudhary P, Meza-Romero R, Calkins E, Kent G, Offner H, Bourdette D, Vandenbark AA.

J Neuroinflammation. 2017 May 6;14(1):100. doi: 10.1186/s12974-017-0873-y.

37.

Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.

Ferrara SJ, Meinig JM, Placzek AT, Banerji T, McTigue P, Hartley MD, Sanford-Crane HS, Banerji T, Bourdette D, Scanlan TS.

Bioorg Med Chem. 2017 May 15;25(10):2743-2753. doi: 10.1016/j.bmc.2017.03.047. Epub 2017 Mar 23.

38.

Sleep and its associations with perceived and objective cognitive impairment in individuals with multiple sclerosis.

Hughes AJ, Parmenter BA, Haselkorn JK, Lovera JF, Bourdette D, Boudreau E, Cameron MH, Turner AP.

J Sleep Res. 2017 Aug;26(4):428-435. doi: 10.1111/jsr.12490. Epub 2017 Jan 17.

39.

Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury.

Hinson HE, Schreiber MA, Laurie AL, Baguley IJ, Bourdette D, Ling GSF.

J Head Trauma Rehabil. 2017 Sep/Oct;32(5):E50-E54. doi: 10.1097/HTR.0000000000000271.

40.

Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette D, Whitham R.

Neurology. 2016 Oct 11;87(15):1532-1533. Epub 2016 Sep 2. No abstract available.

PMID:
27590289
41.

Rituximab for treating multiple sclerosis: Off-label but on target.

Bourdette D.

Neurology. 2016 Nov 15;87(20):2070-2071. Epub 2016 Oct 19. No abstract available.

PMID:
27760871
42.

Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.

Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, Riddehough A, Li DK, McDougall J, Lovera J, Murchison C, Bourdette D.

Mult Scler Relat Disord. 2016 Sep;9:80-90. doi: 10.1016/j.msard.2016.07.001. Epub 2016 Jul 6.

43.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

44.

US health insurance is an obstacle to disease-modifying treatments in MS.

Bourdette D, Patti F.

Neurology. 2016 Jul 26;87(4):346-7. doi: 10.1212/WNL.0000000000002904. Epub 2016 Jun 29. No abstract available.

PMID:
27358336
45.

Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells.

Fiedler SE, Kerns AR, Tsang C, Tsang V, Bourdette D, Salinthone S.

Biochem Biophys Res Commun. 2016 Jun 17;475(1):19-24. doi: 10.1016/j.bbrc.2016.05.021. Epub 2016 May 5.

PMID:
27157139
46.
47.

Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model.

Tagge I, O'Connor A, Chaudhary P, Pollaro J, Berlow Y, Chalupsky M, Bourdette D, Woltjer R, Johnson M, Rooney W.

PLoS One. 2016 Apr 7;11(4):e0152480. doi: 10.1371/journal.pone.0152480. eCollection 2016.

48.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866143
49.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866141
50.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866072

Supplemental Content

Loading ...
Support Center